Literature DB >> 23074079

Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets?

Mark S Cooper, Hong Zhou, Markus J Seibel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23074079     DOI： 10.1002/jbmr.1753

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  7 in total

Review 1.  Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases.

Authors:  Rowan S Hardy; Karim Raza; Mark S Cooper
Journal:  Nat Rev Rheumatol       Date:  2020-02-07       Impact factor: 20.543

2.  GAG and collagen II attenuate glucocorticoid-induced osteoporosis by regulating NF-κB and MAPK signaling.

Authors:  Han Zhu; Meng Wang; Chengjun Zhao; Ruosong Li; Juan Yang; Guangchang Pei; Ting Ye; Xuezhi Zuo; Liu Liu; Octavia Ls Chong Lee Shin; Fengming Zhu; Jie Sun; Huzi Xu; Zhi Zhao; Chujin Cao; Yuxi Wang; Qian Yang; Gang Xu; Rui Zeng; Ying Yao
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

Review 3.  Mechanism and Treatment Strategy of Osteoporosis after Transplantation.

Authors:  Lei Song; Xu-Biao Xie; Long-Kai Peng; Shao-Jie Yu; Ya-Ting Peng
Journal:  Int J Endocrinol       Date:  2015-07-27       Impact factor: 3.257

4.  Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics.

Authors:  S Shoji; A Suzuki; D J Conrado; M C Peterson; J Hey-Hadavi; D McCabe; R Rojo; B K Tammara
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-05-27

Review 5.  Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.

Authors:  Arthur Kavanaugh; Alvin F Wells
Journal:  Rheumatology (Oxford)       Date:  2014-04-10       Impact factor: 7.580

Review 6.  GR Dimerization and the Impact of GR Dimerization on GR Protein Stability and Half-Life.

Authors:  Ann Louw
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

7.  In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects.

Authors:  Victoria Osinski; Dustin K Bauknight; Siva Sai Krishna Dasa; Matthew J Harms; Tobias Kroon; Melissa A Marshall; James C Garmey; Anh T Nguyen; Julia Hartman; Aditi Upadhye; Prasad Srikakulapu; Andrea Zhou; Gavin O'Mahony; Alexander L Klibanov; Kimberly A Kelly; Jeremie Boucher; Coleen A McNamara
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.